Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase I results justify phase II for CuATSM in Parkinson's disease

June 21, 2019

PAOPA displays varied antiparkinsonian activity in vivo

June 21, 2019

Cyxone announces initiation of first-in-human trial of T20K for the treatment of MS

June 21, 2019

FDA allows ReNetX's IND for first-in-human study of AXER-204 to treat spinal cord injury

June 21, 2019

Dying microglia rejuvenate myelin

June 21, 2019

5-HT7 antagonists patented by KAIST, KIST

June 20, 2019

Updated positive results for phase Ib study of resiniferatoxin in knee osteoarthritis pain

June 20, 2019

Intuniv approved in Japan for adults with ADHD

June 19, 2019

Suzhou Institute of Tongji University patents c-Met agonistic antibodies

June 19, 2019

Thioredoxin 1 fusion protein compositions described by Hallym University

June 19, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...